| 晚期非小细胞肺癌维持治疗进展 |
| |
| 引用本文： | 温珍平,韩雅玲.晚期非小细胞肺癌维持治疗进展[J].国际肿瘤学杂志,2016,43(2):148-151. |
| |
| 作者姓名： | 温珍平 韩雅玲 |
| |
| 作者单位： | 内蒙古医科大学附属人民医院肿瘤内科,呼和浩特,010020 |
| |
| 摘 要： | 晚期非小细胞肺癌(NSCLC)标准一线化疗方案的疗效已达到了一个平台期.研究证实化疗药物、分子靶向药物维持治疗可延长晚期NSCLC患者的生存期.免疫治疗成为晚期NSCLC的维持治疗,还需进一步研究证实.
|
| 关 键 词： | 癌 非小细胞肺 药物疗法 分子靶向治疗 免疫疗法 |
Progress of maintenance therapy for advanced non-small-cell lung cancer |
| |
| Institution: | Department of Medical Oncology, the Affiliated People′s Hospital of Inner Mongolia Medical University, Hohhot 010020, China |
| |
| Abstract: | The efficacy of the standard first-line chemotherapy regimen for advanced non-small cell lung cancer (NSCLC) has reached a plateau.Study confirmed that chemotherapy drugs and molecular targeted drug maintenance treatment can prolong the survival of patients with advanced NSCLC.Immunotherapy has become a maintenance treatment for advanced NSCLC,and further research is needed to confirm its efficacy. |
| |
| Keywords: | Carcinoma non-small-cell lung cancer Drug therapy Molecular targeted therapy Immunotherapy |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《国际肿瘤学杂志》浏览原始摘要信息 |
| 点击此处可从《国际肿瘤学杂志》下载免费的PDF全文 |
